The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1485
January 4, 2016
View Complete Issue         Table of Contents 2019 
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
January 4, 2016 (Issue: 1485)
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
Article code: 1485b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.